JP2012509281A - リナクロチドのα結晶形 - Google Patents

リナクロチドのα結晶形 Download PDF

Info

Publication number
JP2012509281A
JP2012509281A JP2011536620A JP2011536620A JP2012509281A JP 2012509281 A JP2012509281 A JP 2012509281A JP 2011536620 A JP2011536620 A JP 2011536620A JP 2011536620 A JP2011536620 A JP 2011536620A JP 2012509281 A JP2012509281 A JP 2012509281A
Authority
JP
Japan
Prior art keywords
linaclotide
ray powder
diffraction pattern
powder diffraction
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011536620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509281A5 (es
Inventor
リテシュ サンフビ，
アンドレアス グリル，
ラフル スラナ，
ハイティアン チュウ，
Original Assignee
アイロンウッド ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイロンウッド ファーマシューティカルズ， インコーポレイテッド filed Critical アイロンウッド ファーマシューティカルズ， インコーポレイテッド
Publication of JP2012509281A publication Critical patent/JP2012509281A/ja
Publication of JP2012509281A5 publication Critical patent/JP2012509281A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011536620A 2008-11-19 2009-11-18 リナクロチドのα結晶形 Pending JP2012509281A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11615608P 2008-11-19 2008-11-19
US61/116,156 2008-11-19
PCT/US2009/065001 WO2010059733A1 (en) 2008-11-19 2009-11-18 Crystalline form of linaclotide

Publications (2)

Publication Number Publication Date
JP2012509281A true JP2012509281A (ja) 2012-04-19
JP2012509281A5 JP2012509281A5 (es) 2013-01-10

Family

ID=42172504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536620A Pending JP2012509281A (ja) 2008-11-19 2009-11-18 リナクロチドのα結晶形

Country Status (6)

Country Link
US (3) US8222201B2 (es)
EP (1) EP2365821A4 (es)
JP (1) JP2012509281A (es)
CA (1) CA2743172A1 (es)
MX (1) MX2011005245A (es)
WO (1) WO2010059733A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502979A (ja) * 2008-09-23 2012-02-02 ゲンキョ テックス エスアー Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体
JP2012502978A (ja) * 2008-09-23 2012-02-02 ゲンキョ テックス エスアー Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010059733A1 (en) * 2008-11-19 2010-05-27 Forest Laboratories Holdings Limited Crystalline form of linaclotide
JP2016521249A (ja) * 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド リナクロチド組成物
EP2950803A1 (en) 2013-01-30 2015-12-09 Sandoz AG Crystalline form of linaclotide
CN104844693B (zh) * 2015-06-10 2018-08-03 成都圣诺生物科技股份有限公司 一种合成利那洛肽的方法
EP3317292B1 (en) * 2015-07-01 2024-01-17 Novetide, Ltd. Solid state forms of linaclotide
CN107163105B (zh) * 2017-06-28 2020-12-11 清华大学 一种天然利那洛肽的结晶方法
EP4194464A1 (en) * 2021-12-13 2023-06-14 Chemi SPA Manufacturing process for the production of linaclotide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087797A1 (en) * 2004-03-09 2005-09-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) * 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081129A1 (fr) * 2001-04-02 2002-10-17 Mitsubishi Materials Corporation Materiau fritte magnetique doux composite ayant une densite elevee et une permeabilite magnetique elevee, et procede permettant sa preparation
SI1594517T1 (sl) 2003-01-28 2007-10-31 Microbia Inc Sestavki za zdravljenje gastrointestinalnih motenj
US20060281682A1 (en) 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
EP3342420A1 (en) 2003-06-13 2018-07-04 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1906951A4 (en) 2005-07-01 2009-05-27 Dynogen Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING HYPOMOTILITY OF THE DIGESTIVE SYSTEM AND RELATED DISORDERS
PE20090696A1 (es) * 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
RU2009144972A (ru) 2007-05-04 2011-06-10 Айронвуд Фармасьютикалз, Инк. (Us) Композиции и способы лечения нарушений, ассоциированных с задержкой соли или жидкости
WO2010059733A1 (en) * 2008-11-19 2010-05-27 Forest Laboratories Holdings Limited Crystalline form of linaclotide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304036B2 (en) * 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005087797A1 (en) * 2004-03-09 2005-09-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502979A (ja) * 2008-09-23 2012-02-02 ゲンキョ テックス エスアー Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体
JP2012502978A (ja) * 2008-09-23 2012-02-02 ゲンキョ テックス エスアー Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体

Also Published As

Publication number Publication date
CA2743172A1 (en) 2010-05-27
US8222201B2 (en) 2012-07-17
EP2365821A4 (en) 2013-09-04
US20120309695A1 (en) 2012-12-06
US20120214750A1 (en) 2012-08-23
US20100125056A1 (en) 2010-05-20
US8293704B2 (en) 2012-10-23
WO2010059733A1 (en) 2010-05-27
MX2011005245A (es) 2011-06-17
EP2365821A1 (en) 2011-09-21

Similar Documents

Publication Publication Date Title
JP2012509281A (ja) リナクロチドのα結晶形
JP6821701B2 (ja) Ｎ−［２−（３−ヒドロキシ−３−メチルブチル）−６−（２−ヒドロキシプロパン−２−イル）−２ｈ−インダゾール−５−イル］−６−（トリフルオロメチル）ピリジン−２−カルボキサミドの結晶形態
KR20210027454A (ko) 2-(3,5-디클로로-4-((5-이소프로필-6-옥소-1,6-디히드로피리다진-3-일)옥시)페닐)-3,5-디옥소-2,3,4,5-테트라히드로-1,2,4-트리아진-6-카르보니트릴의 고체 형태
JP7190612B2 (ja) 置換ピペリジン化合物及びその用途
JP2010507565A (ja) メタスチン誘導体およびその用途
WO2023246656A1 (zh) Sos1蛋白降解靶向嵌合体及其组合物、制剂和用途
WO2018165575A2 (en) Warhead-containing peptidomimetic macrocycles as modulators of bfl-1
US9259403B2 (en) Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
JP2017515900A (ja) ナフタキノンメチルトランスフェラーゼ阻害剤およびそれらの使用
TW201733992A (zh) 製備經取代５，６－二氫－６－苯基苯并［ｆ］異喹啉－２－胺之方法
JP2022522395A (ja) 選択的エストロゲン受容体分解剤の新規な塩
JP2022552187A (ja) 選択的カリウムチャネルモジュレータの固体状態結晶形
TW200911757A (en) Crystalline forms of histone deacetylase inhibitors
EP3972630A1 (en) Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
WO2021050700A1 (en) Cyclooxygenase-2 inhibitors and uses thereof
WO2019246479A1 (en) Form of ponatinib
US20210395232A1 (en) Co-crystal forms of selinexor
US20220315558A1 (en) Polymorphs of 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)methyl)amino)pyrimidin-5-yl)-1h-pyrrole-3-carboxamide
WO2023136279A1 (ja) 置換ピペリジン化合物の結晶並びに置換ピペリジン化合物の塩及びそれらの結晶

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141029